Drug facts

Tirzepatide, pregnancy and contraception

Reviewed August 2026

The contraception part almost nobody mentions¹

Tirzepatide slows how fast the stomach empties, which changes how oral medications are absorbed. The label draws one specific consequence out of that and states it as an instruction, verbatim:

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation.

Read the second half of that sentence again, because it is the part that surprises people: it is not only when you start. Every time the dose goes up, the four weeks begin again. On a standard titration that is a recurring window, not a one-off one.

The same section says hormonal contraceptives that are not taken by mouth should not be affected. So the instruction is about the route, not about hormones.

The label also flags oral medications more generally — it names warfarin as an example of a drug with a narrow therapeutic index worth monitoring. What else it says about interactions →

What section 8.1 actually says²

The risk summary opens with the reasoning rather than the risk: weight loss offers no benefit to a pregnant patient and may cause fetal harm. The label advises telling pregnant patients that weight loss is not recommended during pregnancy, and to discontinue when a pregnancy is recognized. It adds that appropriate weight gain is currently recommended for all pregnant patients, including those with obesity or overweight.

On what is actually known about the drug in pregnancy, it is unusually plain: available data in pregnant patients are insufficient to evaluate a drug-related risk of major birth defects, miscarriage, or other adverse outcomes. That is not a finding of safety and not a finding of harm. It is an absence of data, stated as one.

For context the label gives the background rates in the U.S. general population: 2 to 4% for major birth defects and 15 to 20% for miscarriage in clinically recognized pregnancies — and notes the background risk is already higher in the population this drug is indicated for.

What the animal data showed²

In pregnant rats given tirzepatide during organogenesis, the label reports fetal growth reductions and fetal abnormalities at clinical exposure based on AUC. In rabbits, fetal growth reductions at clinically relevant exposures.

The label adds a qualification that matters for how you read those findings: the effects coincided with the drug’s effects on the mother’s weight and food intake. So it does not separate a direct effect on the fetus from the consequences of the mother eating and weighing less. That is the honest state of it, and animal findings are not a measurement of what happens in people.

There is a registry, and it is not automatic²

The label describes a pregnancy exposure registry monitoring outcomes in women exposed during pregnancy, and encourages patients and providers to contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). Nobody is enrolled by default; it is a phone call somebody has to make.

What a compounded vial changes²

Where to take this³

To a prescriber, and earlier than feels necessary if there is any chance of pregnancy — because the contraception window opens again at every dose increase, which is not something you can plan around after the fact. If you are weighing what else the label does and does not establish, section 8.2 on breastfeeding is the other place where the gap between what is known and what people need to decide is widest.